| __timestamp | Amneal Pharmaceuticals, Inc. | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 84615000 | 302156000 |
| Thursday, January 1, 2015 | 109679000 | 402271000 |
| Friday, January 1, 2016 | 118757000 | 476593000 |
| Sunday, January 1, 2017 | 109046000 | 554336000 |
| Monday, January 1, 2018 | 230435000 | 604353000 |
| Tuesday, January 1, 2019 | 289598000 | 680924000 |
| Wednesday, January 1, 2020 | 326727000 | 737669000 |
| Friday, January 1, 2021 | 365504000 | 759375000 |
| Saturday, January 1, 2022 | 399700000 | 854009000 |
| Sunday, January 1, 2023 | 429675000 | 937300000 |
| Monday, January 1, 2024 | 1009025000 |
Unleashing insights
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. From 2014 to 2023, BioMarin Pharmaceutical Inc. and Amneal Pharmaceuticals, Inc. have shown distinct trends in their SG&A expenditures. BioMarin's expenses have surged by over 200%, peaking at approximately 937 million in 2023. This reflects their aggressive expansion and investment in research and development. In contrast, Amneal's SG&A expenses have grown by about 400%, reaching around 430 million in the same year, indicating a steady but more conservative growth strategy. These trends highlight the differing strategic priorities of these companies, with BioMarin focusing on innovation and Amneal on operational efficiency. As the pharmaceutical landscape evolves, understanding these financial dynamics offers valuable insights into the strategic directions of industry leaders.
Merck & Co., Inc. and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Biogen Inc. and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Viatris Inc. and BioMarin Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or Amneal Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Halozyme Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for BioMarin Pharmaceutical Inc. and Amneal Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and MannKind Corporation
Comparing SG&A Expenses: Amneal Pharmaceuticals, Inc. vs Viking Therapeutics, Inc. Trends and Insights
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.
Operational Costs Compared: SG&A Analysis of Amneal Pharmaceuticals, Inc. and PTC Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Amneal Pharmaceuticals, Inc. or Iovance Biotherapeutics, Inc.